Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other Non-Current Assets (2016 - 2025)

Cumberland Pharmaceuticals' Other Non-Current Assets history spans 16 years, with the latest figure at $3.0 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 6.8% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $3.0 million, up 6.8%, while the annual FY2025 figure was $3.0 million, 6.8% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $3.0 million at Cumberland Pharmaceuticals, roughly flat from $3.0 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $3.5 million in Q2 2021 and bottomed at $2.4 million in Q3 2022.
  • The 5-year median for Other Non-Current Assets is $2.9 million (2025), against an average of $2.9 million.
  • The largest annual shift saw Other Non-Current Assets soared 31.45% in 2021 before it dropped 27.34% in 2022.
  • A 5-year view of Other Non-Current Assets shows it stood at $3.4 million in 2021, then fell by 26.29% to $2.5 million in 2022, then grew by 1.39% to $2.6 million in 2023, then grew by 8.94% to $2.8 million in 2024, then rose by 6.8% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Other Non-Current Assets are $3.0 million (Q4 2025), $3.0 million (Q3 2025), and $2.9 million (Q2 2025).